ANTHRACYCLINE INDUCED CARDIAC TOXICITY: AN IN VITRO MODE
蒽环类药物引起的心脏毒性:体外模式
基本信息
- 批准号:3174799
- 负责人:
- 金额:$ 12.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1983
- 资助国家:美国
- 起止时间:1983-07-01 至 1987-06-30
- 项目状态:已结题
- 来源:
- 关键词:DNA repair anthracyclines arrhythmia beta galactosidase carnitine chemical structure function doxorubicin drug adverse effect electron microscopy electron transport fibroblasts glycolysis heart cell heart contraction mitochondria newborn animals oxidative phosphorylation selenium tissue /cell culture tocopherols ubiquinone
项目摘要
The dose-dependent cardiomyopathy that develops on chronic administration
of adriamycin (ADR), an anthracycline effective in the treatment of a wide
variety of human malignancies, severely limits its long-term usage. A
number of studies aimed at understanding the cardiopathogenic nature of
this drug have been reported. However, the mechanism of cardiotoxicity
remains unknown. The aim of this project is to investigate various aspects
of our in vitro pulsating cardiac cell system as they relate to ADR
cardiotoxicity in man. The uniqueness and importance of an in vitro
cardiac cell system is that it provides a sensitive measure of the
metabolic effects of drugs on cellular function. The consistency and
precision of autorhythmicity of heart cells in culture offers a unique way
to investigate these effects. A microscope stage has been designed here to
accurately control temperature and pH, two variables to which cardiac cell
function is particularly sensitive. An electronic system has been
developed which quantitatively records beating patterns. Other techniques
that will be used to study the mechanism of toxicity of ADR, ADR analogues
(AD 32) and other anti-cancer agents include: Light and electron
microscopy, to assess structural damage; RNA and DNA assays, to evaluate
synthesis and repair; metabolic inhibitors, as probes for distinguishing
between glycolytic and electron transport effects and ATP assays to
determine the biochemical effects of these agents. These studies are
anticipated to lead to methods of preventing cardiotoxicity.
慢性给药所致的剂量依赖性心肌病
阿霉素(ADR),一种治疗广泛性黄斑变性的蒽环类药物
多种人类恶性肿瘤,严重限制了其长期使用。一个
旨在了解心脏致病本质的多项研究
据报道,这种药物。然而,心脏毒性的机制
仍然不为人知。这个项目的目的是调查各个方面
我们的体外搏动心脏细胞系统与ADR的关系
对人类的心脏毒性。体外培养的独特性和重要性
心脏细胞系统是它提供了一种敏感的测量
药物对细胞功能的代谢影响。一致性和
培养心肌细胞自律性的精确度提供了一种独特的方法
来研究这些影响。这里已经设计了一个显微镜工作台来
准确控制温度和pH,这两个变量对心肌细胞
功能尤其敏感。一个电子系统已经被
开发了一种定量记录跳动模式的工具。其他技术
这将用于研究ADR、ADR类似物的毒性机制
(公元32)和其他抗癌药物包括:光和电子
显微镜,用于评估结构损伤;RNA和DNA分析,用于评估
合成和修复.作为区分的探针的代谢抑制物
糖酵解和电子传递效应与ATP测定之间的关系
确定这些制剂的生物化学效应。这些研究是
预计将导致预防心脏毒性的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THEODORE J LAMPIDIS其他文献
THEODORE J LAMPIDIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THEODORE J LAMPIDIS', 18)}}的其他基金
Role of Mitochondria and Glycolysis in Tumor Cell MDR
线粒体和糖酵解在肿瘤细胞 MDR 中的作用
- 批准号:
6861020 - 财政年份:1983
- 资助金额:
$ 12.47万 - 项目类别:
ANTHRACYCLINE CARDIOTOXICITY: AN IN VITRO MODEL
蒽环类药物的心脏毒性:体外模型
- 批准号:
3174800 - 财政年份:1983
- 资助金额:
$ 12.47万 - 项目类别:
ANTHRACYCLINE CARDIOTOXICITY: AN IN VITRO MODEL
蒽环类药物的心脏毒性:体外模型
- 批准号:
3174794 - 财政年份:1983
- 资助金额:
$ 12.47万 - 项目类别:
ANTHRACYCLINE CARDIOTOXICITY: AN IN VITRO MODEL
蒽环类药物的心脏毒性:体外模型
- 批准号:
3174801 - 财政年份:1983
- 资助金额:
$ 12.47万 - 项目类别:
Role of Mitochondria and Glycolysis in Tumor Cell MDR
线粒体和糖酵解在肿瘤细胞 MDR 中的作用
- 批准号:
6512472 - 财政年份:1983
- 资助金额:
$ 12.47万 - 项目类别:
DRUG SELECTIVITY IN CARDIAC AND MDR TUMOR CELLS
心脏和 MDR 肿瘤细胞的药物选择性
- 批准号:
2089227 - 财政年份:1983
- 资助金额:
$ 12.47万 - 项目类别:
PROBING MDR & MRP WITH SIMPLE COMPOUNDS & ANTHRACYCLINES
探索MDR
- 批准号:
2393426 - 财政年份:1983
- 资助金额:
$ 12.47万 - 项目类别:
Anti-tumor Activity of Sugar Analogs via Blocking Glycolysis vs Glycosylation
糖类似物通过阻断糖酵解与糖基化的抗肿瘤活性
- 批准号:
8092860 - 财政年份:1983
- 资助金额:
$ 12.47万 - 项目类别:
Anti-tumor Activity of Sugar Analogs via Blocking Glycolysis vs Glycosylation
糖类似物通过阻断糖酵解与糖基化的抗肿瘤活性
- 批准号:
7866499 - 财政年份:1983
- 资助金额:
$ 12.47万 - 项目类别:
Anti-tumor Activity of Sugar Analogs via Blocking Glycolysis vs Glycosylation
糖类似物通过阻断糖酵解与糖基化的抗肿瘤活性
- 批准号:
7462352 - 财政年份:1983
- 资助金额:
$ 12.47万 - 项目类别:
相似海外基金
RUI: BIOPOLYMER - BIObricks POLYketide Metabolic EngineeRing platform for unraveling the biosynthesis of higher anthracyclines
RUI:BIOPOLYMER - BIObricks 聚酮化合物代谢工程平台,用于揭示高级蒽环类药物的生物合成
- 批准号:
2321976 - 财政年份:2024
- 资助金额:
$ 12.47万 - 项目类别:
Standard Grant
Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines
用纳米颗粒封装的蒽环类药物减轻长期心脏毒性
- 批准号:
10378678 - 财政年份:2021
- 资助金额:
$ 12.47万 - 项目类别:
Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines
用纳米颗粒封装的蒽环类药物减轻长期心脏毒性
- 批准号:
10195941 - 财政年份:2021
- 资助金额:
$ 12.47万 - 项目类别:
Validation and Implementation of Polygenic-Risk Prediction Models for Anthracyclines and Cisplatin in Pediatric Oncology
儿科肿瘤学中蒽环类药物和顺铂多基因风险预测模型的验证和实施
- 批准号:
429174 - 财政年份:2019
- 资助金额:
$ 12.47万 - 项目类别:
Studentship Programs
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines
STOP-CA:他汀类药物可预防蒽环类药物的心脏毒性
- 批准号:
9351286 - 财政年份:2016
- 资助金额:
$ 12.47万 - 项目类别:
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines
STOP-CA:他汀类药物可预防蒽环类药物的心脏毒性
- 批准号:
9176736 - 财政年份:2016
- 资助金额:
$ 12.47万 - 项目类别:
Linking defects in the uptake transporter OCT1 with cancer patients resistance towards anthracyclines
将摄取转运蛋白 OCT1 的缺陷与癌症患者对蒽环类药物的耐药性联系起来
- 批准号:
357190 - 财政年份:2016
- 资助金额:
$ 12.47万 - 项目类别:
Operating Grants
Anthracyclines disrupt Ca2+ signalling in cardiomyocytes: a contribution to cardiac toxicity
蒽环类药物破坏心肌细胞中的 Ca2 信号传导:导致心脏毒性
- 批准号:
nhmrc : 1021342 - 财政年份:2012
- 资助金额:
$ 12.47万 - 项目类别:
Project Grants
Examination of the Molecular Pharmacology of Anthracyclines Induced via their Interaction with Iron
通过与铁相互作用诱导的蒽环类药物的分子药理学研究
- 批准号:
nhmrc : 457310 - 财政年份:2007
- 资助金额:
$ 12.47万 - 项目类别:
NHMRC Project Grants














{{item.name}}会员




